Skip to content

Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer

GeneSearch™ Breast Lymph Node (BLN) Assay for Molecular Testing Protocol

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00551278
Enrollment
80
Registered
2007-10-30
Start date
2007-10-31
Completion date
2009-12-31
Last updated
2016-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

sentinel lymph node, metastasis, molecular pathology

Brief summary

The purpose of this trial is to show adequate assay performance on clinical samples tested in real time at the clinical site.

Detailed description

This study will determine the sensitivity, specificity, negative predictive value, and positive predictive value of the GeneSearch™ BLN Assay in patient samples by comparing its performance to that of the current methods -- permanent section Hematoxylin and Eosin (H&E) staining with IHC. Additional marker testing using probes associated with nodal metastases may be used in the assay performance calculations. The observed performance measures will be compared to those obtained in the larger U.S. registration trial to show that there are no differences in the assay's performance.

Interventions

For in vitro diagnostic use only. The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes. Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required.

Sponsors

Janssen Diagnostics, LLC
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Previous diagnosis of carcinoma of the breast * Patient scheduled for sentinel lymph node dissection as per standard of care at the clinical site * 18 years or older * Female or male, and * Able and willing to give consent to participate in the study

Exclusion criteria

* Patients taking part in other research studies that would interfere with their full participation in this study

Design outcomes

Primary

MeasureTime frame
The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the GeneSearch™ BLN Assay by comparing its performance to permanent section Hematoxylin and Eosin (H&E) staining with IHC.1 month

Secondary

MeasureTime frame
A secondary objective will assess the timing and logistical aspects of introducing a real time molecular test within the pathology lab.1 day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026